• This is Vicore
    • Our story
    • Our ambition and strategic priorities
    • Collaborations and partnerships
    • Scientific Advisors
    • Senior Leadership Team
    • Board of Directors
  • Science
    • Scientific rationale
    • ATRAG MoA in IPF
    • Intellectual property and orphan drug designation
    • Publications
      • Key publications
      • Posters
  • Our programs
    • Pipeline
    • ASPIRE IPF Ph2b trial
    • Rare lung diseases
      • Buloxibutid (C21) – IPF
      • Almee – PF anxiety
    • Future ATRAG indications
    • Our drug discovery engine
  • Almee™
  • Career
    • Our collaborative business model
    • Open positions
    • Contact
  • Media
    • Press releases (ENG)
    • Pressmeddelanden (SE)
    • Image bank
  • Investors
    • Investors
      • Overview
      • Press releases
      • Rights Issue, September 2024
      • The share
      • Financial reports
      • Financial calendar
      • Events & Presentations
      • Corporate governance
      • Image bank
      • Investor Relations contact
    • Investerare (SE)
      • Översikt
      • Pressmeddelanden
      • Företrädesemission September 2024
      • Aktien
      • Finansiella rapporter
      • Finansiell kalender
      • Events & Presentationer
      • Bolagsstyrning
      • Bolagsstämma
      • Bildbank
      • Investerarkontakt
  • Patients and caregivers
    • IPF
      • Background
      • Patient stories
      • Patient advocacy organizations
    • Transparency
    • Expanded Access Policy
logo
  • This is Vicore
    • Our story
    • Our ambition and strategic priorities
    • Collaborations and partnerships
    • Scientific Advisors
    • Senior Leadership Team
    • Board of Directors
  • Science
    • Scientific rationale
    • ATRAG MoA in IPF
    • Intellectual property and orphan drug designation
    • Publications
      • Key publications
      • Posters
  • Our programs
    • Pipeline
    • ASPIRE IPF Ph2b trial
    • Rare lung diseases
      • Buloxibutid (C21) – IPF
      • Almee – PF anxiety
    • Future ATRAG indications
    • Our drug discovery engine
Almee™
  • Career
    • Our collaborative business model
    • Open positions
    • Contact
  • Media
    • Press releases (ENG)
    • Pressmeddelanden (SE)
    • Image bank
  • Investors
    • Investors
      • Overview
      • Press releases
      • Rights Issue, September 2024
      • The share
      • Financial reports
      • Financial calendar
      • Events & Presentations
      • Corporate governance
      • Image bank
      • Investor Relations contact
    • Investerare (SE)
      • Översikt
      • Pressmeddelanden
      • Företrädesemission September 2024
      • Aktien
      • Finansiella rapporter
      • Finansiell kalender
      • Events & Presentationer
      • Bolagsstyrning
      • Bolagsstämma
      • Bildbank
      • Investerarkontakt
  • Patients and caregivers
    • IPF
      • Background
      • Patient stories
      • Patient advocacy organizations
    • Transparency
    • Expanded Access Policy
logo
Home / Investerare (SE) / Listningsprospekt
Översikt Pressmeddelanden Företrädesemission September 2024
  • Aktien
    • Aktien
    • Aktieägare
    • Ägande styrelse och ledning
    • Aktiekapitalets utveckling
    • Emissioner
    • Analytiker
    • Listningsprospekt
Finansiella rapporter Finansiell kalender Events & Presentationer
  • Bolagsstyrning
    • Bolagsstyrningsrapporter
    • Bolagsstämma
    • Valberedning
    • Styrelsen
    • Revisionsutskott
    • Ersättningsutskott
    • Vetenskapligt utskott
    • Ledning
    • Arvoden och ersättningar
    • Revisorer
    • Bolagsordning
Bildbank Prenumerera på nyheter Investerarkontakt

Listningsprospekt

Vicore Pharma upprättade ett prospekt i samband med att bolagets aktier noterades på Nasdaq Stockholms huvudlista den 27 september 2019. Sista dag för handel på Nasdaq First North Growth Market var den 26 september.

Vicore Pharma Holding Prospekt

logo
Vicore Pharma’s offices

Kornhamnstorg 53
SE-111 27 Stockholm, Sweden

Agern Allé 5A
DK-2970 Hørsholm, Denmark

Cambridge Innovation Center
14th floor, One Broadway, Cambridge
MA 02142, USA

We'd love to hear from you!
Phone: +46 (0) 31 788 05 60 Mail: info@vicorepharma.com
Billing and mailing address:

Vicore Pharma
Postbox 14
414 52 Gothenburg, Sweden

Quick links
Contact Subscribe to press releases Privacy Policy Cookies